logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Charles Joseph Eyermann

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2008-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles Joseph Eyermann. Retrieved from https://idiyas.com/inventor/charles-joseph-eyermann-8mkv4etl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal3 out of 1,534 
 
Astrazeneca Ab
 patents

Years Active: 2008-2012

Loading Chart...
3 patents (USPTO):Explore Patents
1. 8124602 - Compounds for the treatment of multi-drug resistant bacterial infections (2012-02-28),
2. 7875715 - Compounds for the treatment of multi-drug resistant bacterial infections (2011-01-25),
3. 7371757 - Fused heterocycles as inhibitors of glutamate racemase(MURI) (2008-05-13),

Title: Charles Joseph Eyermann: Innovator in Antibacterial Compounds

Introduction

Charles Joseph Eyermann is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of antibacterial treatments, holding a total of 3 patents. His work focuses on developing compounds that address multi-drug resistant bacterial infections, which is a critical area of research in modern medicine.

Latest Patents

Eyermann's latest patents include innovative compounds for the treatment of multi-drug resistant bacterial infections. These compounds demonstrate antibacterial activity and involve processes for their preparation. The pharmaceutical compositions containing these compounds serve as active ingredients in medicaments designed for treating bacterial infections in warm-blooded animals, including humans. His inventions are particularly relevant in the ongoing battle against antibiotic resistance, providing new avenues for effective treatment.

Career Highlights

Charles Joseph Eyermann is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry. Eyermann's dedication to innovation in healthcare has positioned him as a key figure in the fight against bacterial infections.

Collaborations

Eyermann has collaborated with notable colleagues, including Marshall Morningstar and Gloria Breault. These partnerships have facilitated the exchange of ideas and expertise, enhancing the development of effective antibacterial solutions.

Conclusion

Charles Joseph Eyermann's contributions to the field of antibacterial compounds are invaluable. His innovative work at AstraZeneca AB and his focus on addressing multi-drug resistant bacterial infections highlight the importance of continued research in this area. His patents represent a significant step forward in the development of effective treatments for bacterial infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…